Anti-Cancer Agents and Biological Therapy
Clinical Practice Guidelines
Latest ESMO videos
E-Learning
ESMO E-Learning: Optimal Management of Cancer-Associated Thrombosis (CAT) - An Update
ESMO E-Learning: Treatment of Locally Advanced NSCLC with Chemo-radiotherapy
ESMO E-Learning: PARP Inhibitors: Past, Present and Future
ESMO E-Learning: Cardiotoxicity in Oncology Practice
ESMO V-Learning: BRCA Across Tumour Types
Meeting resources
397MO - Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305
Presenter: Markus Moehler
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
Treatment of advanced oesophageal cancer in 2024
Presenter: Kei Muro
Session: Oesophago-gastric cancer
Resources:
Slides
Webcast
Treatment of advanced gastric cancer in 2024
Presenter: Elizabeth Smyth
Session: Oesophago-gastric cancer
Resources:
Slides
Webcast
Oligometastatic gastric cancer: Truth or myth?
Presenter: Christelle de la Fouchardiere
Session: EORTC session: Hot topics and methodological perspectives in GI oncology trials
Resources:
Slides
Webcast
Invited discussant LBA3 and LBA4
Presenter: Elizabeth Smyth
Session: Proffered Paper session
Resources:
Slides
Webcast